Conclusion: Compared to placebo, venlafaxine was associated with a lower incidence of dizziness, while desvenlafaxine, sertraline, and vortioxetine were associated with a higher incidence of nausea/vomiting. In conclusion, desvenlafaxine, paroxetine, venlafaxine, and vortioxetine had reasonable efficacy, acceptability, and tolerability in the treatment of adults with stable MDD.
Sertraline side effects
Across 136 first-hand reports, people mentioned a side effect 23 times (about 17 per 100 reports). The most common: fatigue, numbness, brain fog. User reports show what people notice — they can't tell you whether Sertraline is safe for you.
Reported side effects
What got worse for some people
In their own words
“Zoloft changed everything. It gave me what felt like superpowers: hard erections and the ability to last up to an hour.”
“I'm meant to be on 75mg of zoloft but I only take 50mg because 75 causes migraines. ... the zoloft helped my panic disorder and ocd but if anything made my depression worse.”
“I *felt* best on Zoloft...but had absolutely zero libido. Guys also report similar difficulties cumming.”
“It's a side effect of Zoloft. It was prescribed to me for a while after my wife died... They actually prescribe Zoloft for people with premature ejaculation issues.”
“I'm coming off sertraline, so on low dose, taking every other day. the sert. made me total zombie. The combo yesterday was freaking awesome, I felt good, totally in the zone, much brighter mood.”
“I gained weight and lost sexual function on both Zoloft and Lexapro. Those are both SSRIs. I lost weight and gained sexual function on Wellbutrin and Buspar.”
Is Sertraline safe? What the research covers
Conclusion: Despite the scarcity of high-quality evidence, fluoxetine (alone or in combination with CBT) seems to be the best choice for the acute treatment of moderate-to-severe depressive disorder in children and adolescents. However, the effects of these interventions might vary between individuals, so patients, carers, and clinicians should carefully balance the risk-benefit profile of efficacy, acceptability, and suicide risk of all active interventions in young patients with depression on a case-by-case basis.